Biotechnology company BioVaxys Technology Corp (CSE:BIOV) (FRA:5LB) stated on Friday that it has filed an application for a pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research.
The company added that the pre-IND meeting is a critical step in the US regulatory process as it provides an opportunity for study sponsoring companies to obtain clarity from the US FDA on clinical trial design, clinical material manufacturing and quality control.
In addition, the company has submitted a briefing package with the US FDA for its T-cell immune response diagnostic for SARS-CoV-2, the Covid-T. It now awaits a written response on the pre-IND briefing package.
According to the company, Covid-T uses Delayed-type hypersensitivity (DTH), which is known as a measure of T-cell immunity and has been used for many years for other infectious diseases. The test is carried out by using a small amount of synthetic test material, B. SARS-Cov-2 spike protein, placed intradermally and the site examined 24 hours later for slight induration. Skin test antigens are considered biological products and are regulated by the Office of Vaccine Research and Review (OVRR) of CBER.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer